By Sophia Smith, PhD, Chair of Hodgkin’s International
During my sabbatical at the Netherlands Cancer Institute (NKI), I have been working closely with investigators affiliated with the BETER program, one of the world’s most comprehensive survivorship initiatives for people treated for Hodgkin lymphoma (HL). BETER (short for Better care after HL) was established to systematically identify, prevent, and manage the long-term and late adverse effects of HL treatment using a risk-based, personalized follow-up approach. Embedded within BETER is the INSIGHT study,